Key result
Apixaban was noninferior to warfarin for the resolution of post-MI left ventricular thrombus at 3 months (76.0% vs 80.0%; P<0.036 for noninferiority).
Why the study?
Direct oral anticoagulants are frequently used to treat post-myocardial infarction left ventricular thrombus, but the efficacy and safety of apixaban compared to standard warfarin therapy required evaluation.
Does apixaban improve left ventricular thrombus resolution in patients with post-myocardial infarction left ventricular thrombus compared to warfarin?
Comparison
Apixaban 5 mg twice daily vs warfarin (target INR 2-3)
Design
Open-label randomized controlled noninferiority trial
Follow-up
6 months
Authors
Loading...
Apixaban noninferior to warfarin for post-MI LVT resolution; extends anticoagulation options with RCT confirmation.
RCT (n=50)
Open-label
randomized
Yes
Does apixaban improve left ventricular thrombus resolution in patients with post-myocardial infarction left ventricular thrombus compared to warfarin?
Absolute Event Rate: 76% vs 80%
p-value: p=< 0.036 for noninferiority
Apixaban is non-inferior to warfarin for the resolution of post-myocardial infarction left ventricular thrombus at 3 months.
Youssef et al. (2022) conducted an RCT in Post-myocardial infarction left ventricular thrombus (n=50). Apixaban vs. Warfarin was evaluated on LVT resolution at 3 months (p=< 0.036 for noninferiority). Apixaban was noninferior to warfarin for the resolution of post-MI left ventricular thrombus at 3 months (76.0% vs 80.0%; P<0.036 for noninferiority).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: